

Investment in COVID-19 Health Response and Vaccination (As at 15 April 2021)			
Funding Component	Total (\$m)	Total Expenditure As at 31 Mar 21 (\$m)	Details
Funding Mechanisms	1,062.9	*	- Payments for each vaccination dose delivered by the States; - Funding under the Medicare Benefit Schedule Practice Incentive Payments and related programs for COVID-19 vaccination of the Australian population; and - Primary Care Support through GP led Respiratory Clinics, Primary Health Networks, Indigenous Health and CALD organisations.
Surge Workforce and Training	251.3	2.7	Commonwealth contracted surge workforce to support the rollout of the COVID-19 Vaccination Program, includes training through Aust College of Nursing.
Vaccine Distribution, Logistics and Additional Consumables	202.3	12.8	To engage partners to distribute COVID-19 vaccines to locations across Australia, includes the purchase of ultra-cold -80c freezers.
National Clinical Evidence Taskforce (Monash University)	1.7	0.8	Extending departmental funding for the National COVID-19 Clinical Evidence Taskforce to continue to deliver nationally up-to-date evidence-based clinical guidelines to support clinicians with caring of people with COVID-19.
Initial Support for COVID-19 Vaccine Treatment Procurement and Implementation	7.8	*	Funding to establish and support the COVID-19 Vaccine Taskforce Division.
Peripherals to enable COVID-19 vaccine administration	24.7	5.1	To purchase vaccine related consumables.
Phase 1 Data works	47.8	*	Updates to digital health systems to support Phase One of the national roll-out of the COVID-19 Vaccination Program.
End-to-End Digital Solution	232.2	*	Updates to digital health systems to support the COVID-19 Vaccination Program.
Program Delivery Support	37.9	*	Additional resources for the Department of Health through the COVID-19 Vaccine Taskforce to lead and implement Australia's Vaccine Rollout Strategy.
COVID-19 Vaccine Advance Purchase Agreements	3,865.9	^	
Initial investment to the Gavi COVAX Facility (up to 25.6 million doses)	123.2	127.1	Agreement with Gavi to secure access of up to 25,651,000 doses from the COVAX Facility under the self-financing optional purchase model.
National Communications Campaign	39.6	5.5	To develop and rollout COVID-19 vaccine communications to support the COVID-19 Vaccination Program.
Research Investment & Vaccine Development	371.7	58.1	Includes research into diagnostics, vaccine development, antiviral development, clinical trials, digital health research infrastructure and research into the human immune response to COVID-19 infection.
COVID-19 Vaccines for the Pacific and South East Asia	523.2	-	To support access to safe and effective COVID-19 vaccines for the Pacific and Southeast Asia.
Pledge to Gavi	300.0	-	Pledge to Gavi, the Vaccine Alliance, to pool global resources to accelerate the development and distribution of COVID-19 vaccines.
Investment to secure COVID-19 vaccines for developing countries	80.0	-	Investment to secure COVID-19 vaccines for developing countries through the Advance Market Commitment component of Gavi Facility.
Total	7,172.2	212.2	

Notes:

* Not currently available.

^ Commercial-in-Confidence.

1) This table Includes Departmental and Administered funding.

2) Total Commitment figures contained in the above table reconcile to our Financial systems as at 15 April 2021.

3) Total Expenditure figures contained in the above table reconcile to our Financial systems as at 31 March 2021.